FDA Issues Formal Guideline Waiving Clinical Efficacy Studies for Biosimilars, Confirming Professor Niazi’s 15-Year Campaign to Cut Biologic Drug Costs
A Landmark Regulatory Shift Validates Professor Sarfaraz K. Niazi’s Vision to Make Biologics as Affordable as Generics CHICAGO,…
